CompletedPhase 2ACTRN12611000735954

Does exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) attenuate the glycaemic response to small intestinal nutrient in critically ill patients?

The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) on glycaemia in critically ill patients

Sponsor

Adam Deane

Enrollment

20 participants

Start Date

Aug 25, 2011

Study Type

Interventional

Conditions

Blood Glucose

Summary

The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 (both hormones released from the gastrointestinal tract) has a glucose lowering effect in critically ill patients

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether combining two gut hormones (GIP and GLP-1) can reduce high blood sugar levels in critically ill, mechanically ventilated patients aged 18 to 85 who are receiving nutrition through a post-pyloric feeding tube. Participants must not have a history of diabetes. The research explores a potential new approach to managing blood sugar spikes in intensive care patients.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Study Drug: Glucose-dependent insulinotropic polypeptide (GIP)at 2pmol.kg.min & glucagon-like peptide-1 (GLP-1) at 1.2pmol.kg.min Infused intravenously from 0-270mins or Control: 0.9% saline & G

Study Drug: Glucose-dependent insulinotropic polypeptide (GIP)at 2pmol.kg.min & glucagon-like peptide-1 (GLP-1) at 1.2pmol.kg.min Infused intravenously from 0-270mins or Control: 0.9% saline & GLP-1 at 1.2pmol/kg/min Infused intravenously from 0-270mins Patients will be studied on consecutive days (i.e. 24 hour washout period)

Locations(1)

The Royal Adelaide Hospital - Adelaide

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000735954

Related Trials

A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population

NCT070434781 location